The distal segment of an injured nerve normally undergoes Wallerian degeneration within 24-48 hours 1 . Axon death in diverse neurodegenerative diseases follows the same final pathway. The earliest observable events, disruption of the cytoskeleton and blebbing of the axolemma, occur within the axon itself, whereas later stages also involve the reaction of other cell types, such as Schwann cells and macrophages. It is not known how Wallerian degeneration is initiated, but the mechanism is clearly distinct from neuronal cell body degeneration 2,3 .
β-actin promoter. Four transgenic lines (4830, 4836, 4839 and 4858) expressed the protein from multi-copy integrations. The transgene expression level increased in the order 4839 < 4830 ≈ 4858 < Wld S ≈ 4836 (Fig. 3) . Line 4858, whose expression level and phenotype was similar to line 4830, is not discussed further. Like spontaneous Wld S mice, transgenic mice up to at least one year old showed no unusual overt phenotype.
Structural preservation of transected axons
First we tested the structural preservation of axons following unilateral sciatic nerve transection, analyzing a nerve segment 2-4 mm distal to the lesion after 3-5 days. Electron microscopy revealed that almost all axons in line 4836 homozygotes, separated from their cell bodies for five days, contained fully preserved cytoskeleton ( Fig. 1 and Supplementary Fig. 1 , available on the Nature Neuroscience web site), thus successfully reproducing the Wld S phenotype. In contrast, all myelinated and unmyelinated wild-type axons showed clear signs of degeneration. Line 4830 axons were partially protected in accordance with the lower transgene expression level in this line ( Fig. 3a) and line 4839 homozygotes also showed partial protection after on nearby genes. Indeed, mutation of the human homolog of one neighboring gene, kinesin family 1b (Kif1b) 21 , causes axon loss in Charcot-Marie-Tooth disease type 2A 22 .
To test the hypothesis that the Ube4b/Nmnat chimeric gene confers the slow Wallerian degeneration phenotype, we expressed it in transgenic mice. The Wld S phenotype was reproduced fully in one line and partially in other lines according to transgene expression level, thus proving that the chimeric gene is the Wld gene. We detected Wld protein in nuclei of neurons but neither in axons nor in Schwann cells, implicating the existence of downstream factor(s) that mediate the protective effect. Further, we report that the Wld protein showed Nmnat enzyme activity and acted in a strongly dose-dependent manner.
RESULTS

Generation of transgenic mice
To test the role of the Ube4b/Nmnat chimeric gene, we generated transgenic mice expressing the Ube4b/Nmnat cDNA from a Thus, motor nerve conduction, synaptic transmission, vesicle recycling and motor nerve terminal morphology were preserved in a dose-dependent manner, with line 4836 showing a level of protection similar to Wld S . Axons evidently persisted longer than functional motor nerve terminals, supporting the hypothesis that synaptic degeneration, at least in Wld S mice, differs from that of axons and neuronal cell bodies 25 .
Protection depends on Wld protein expression level
The above experiments suggested that the degree of protection depends on the expression level of Wld protein. This was surprising because heterozygous Wld S axons at short survival times degenerate only slightly faster than those of homozygotes 5 . We quantified Wld protein expression in each mutant strain to determine the level required to preserve cytoskeletal protein and axon structure for 3-5 days (Fig. 3) . At lower expression levels, both measures of axon preservation indicated a strong dose-dependence. Axon counts at 3 days differed significantly between hemizygous 4836 and hemizygous 4830 mice (p < 0.001). Significant differences between homozygotes and hemizygotes of a single line (p < 0.01 for 4830; p < 0.001 for 4839) indicated that this is not a line-specific silencing effect 26 . Line 4839 hemizygotes were even indistinguishable from wild-type mice in neurofilament western blotting (NF-200 band, Fig. 3a) , light microscopy ( Fig. 3b) and electron microscopy (data not shown), despite expressing a small amount of the Wld protein (Fig. 3a) . Thus, it is necessary for expression of Wld to reach a threshold level to exert a significant protective effect.
To investigate whether the protective effect of Wld protein plateaus at higher expression levels, and to test axon protection in (Fig. 3a) . 
Functionally competent motor axons and synapses
Next we tested whether axons were functionally as well as structurally preserved. Nerve-muscle preparations of flexor digitorum brevis (FDB) were isolated and stimulated 2-5 days after lesion. Axotomized wild-type muscles showed no response at these time points. In axotomized transgenics, however, as in the Wld S mutant 23 , conduction of action potentials and synaptic transmission at neuromuscular junctions persisted for at least three days (Fig. 2) . In a homozygous 4836 mouse, 80% (12/15) of muscle fibers responded to nerve stimulation three days after sciatic nerve section (for example, Fig. 2a ). In another 4836 homozygote, functional innervation even after 5 days was indicated by 73% (22/30) of FDB muscle fibers showing spontaneous miniature endplate potentials (MEPP) and some responding to nerve stimulation (data not shown). Weaker, and sometimes more variable, responses indicating low quantal content were observed both in line 4836 hemizygotes ( Fig. 2b) and homozygous 4830 mice. In the latter, 50% (12/24) and 30% (8/25) of fibers from two mice responded to stimulation two days after lesion. These weaker responses are in accord with the lower expression levels of the Wld protein (see below). Axotomized 4836 nerve terminals also recycled synaptic vesicles, visualized by activity-dependent staining with the styryl dye FM1-43, both upon incubating lumbrical muscles in a depolarizing solution ( Fig. 2c and d ) and upon stimulation of the distal stump of axotomized tibial nerve. Preservation of pre-and postsynaptic structures was confirmed using antibodies against NF165/SV2 and TRITC-α-bungarotoxin respectively ( Fig. 2e and  f) . In two line 4836 homozygotes, 87-93% of endplates (n = 154 and 164) were occupied or partially occupied (8%) by nerve terminals 5 days after axotomy, similar to Wld S mice 23, 24 . Fewer than 50% (n = 187 and 210) were occupied in two 4836 hemizygotes after 3 days, and fewer still in 4830 homozygotes, again reflecting the lower transgene expression. transgenic mice under still more stringent conditions, we extended these studies to post-lesion times of 10-14 days. Fourteen days after transection, protection of axons in line 4836 homozygotes (69-73%) was as strong as that in Wld S homozygotes (73-78%; Figs. 3c and 4), again indicating full reproduction of the Wld S phenotype. Protection in line 4836 hemizygotes, however, was considerably weaker (35% after 10 days and only 7% after 14 days). Thus, the extent of axon protection differed far more between 4836 homo-and hemizygotes after 14 days than after 3-5 days, indicating that dose-dependence still operates at higher Wld expression levels. It follows that if Wld protein expression could be raised still further, an even stronger protective effect than in Wld S and line 4836 mice could be achieved.
Wld is a predominantly nuclear protein
To determine whether the Wld protein could itself be the protective factor in axons, we determined its intracellular loca- tion. An antiserum labeling the N-terminal 70 amino acids of Wld protein and Ube4b detected mainly a punctate nuclear pattern in Wld S and transgenic neurons (Fig. 5a, c, g and h) and this signal was absent in wild-type neurons ( Fig. 5b and i) . There was no detectable signal either in motor axon terminals ( Fig. 5d-f) , which can be preserved by the Wld gene ( Fig. 2e and f) , or in sciatic nerve axons ( Supplementary Fig. 2 , available on the Nature Neuroscience web site). Swollen endbulbs of 24-hour transected central and peripheral nervous system axons, which accumulate other axonal proteins, also lacked Wld protein signal (data not shown). In addition, the antibody weakly labeled the normal Ube4b protein in cytoplasm of wild-type mice, so additional labeling of any small amount of cytoplasmic Wld protein might not be distinguishable.
Although the Wld S phenotype is intrinsic to neurons 2, 7, 8 , Wld protein was also detected as a punctate nuclear stain in other cell types in both Wld S and transgenic mice ( Fig. 5d and e) . There was no sign of Wld protein in glial cells (Fig. 5c-e) , although previous RT-PCR (reverse transcription-polymerase chain reaction) data indicate there may be a small amount in Schwann cells 18 . It is highly unlikely that expression in other cell types is required Fig. 6a ). The total content of NAD + , however, was not significantly altered (p = 0.2; Fig. 6b) . Therefore, the Wld protein confers an increase in Nmnat activity without altering the steady-state level of NAD + .
DISCUSSION
We showed that the Ube4b/Nmnat chimeric gene is necessary and sufficient to protect injured axons for two weeks. We conclude that the Ube4b/Nmnat chimeric gene is the Wld gene, which encodes a unique neuroprotective factor for axons. It is important now to determine whether protection requires Ube4b sequences, Nmnat sequences, or both. The yeast homolog of Ube4b is required to multi-ubiquitinate proteins 30 and a direct link between ubiquitination and axon degeneration comes from the Uch-l1 mutation in gracile axonal dystrophy 31 . However, the Wld protein contains only 70 of 1,173 amino acids from Ube4b, and these are absent from the yeast homolog. They are therefore unlikely to confer multi-ubiquitination activity but may have a related role. The protective mechanism may be linked to the nuclear location of the Wld protein and perhaps to the non-homogeneous intranuclear distribution. Possibilities include sequestering of ubiquitination factors by protein-protein interactions and ubiquitination within the nucleus altering transcription factor stability or RNA processing, leading to an axon effect mediated by unknown proteins. Regulated nuclear transport of other ubiquitination factors can control ubiquitin-mediated degradation of nuclear substrates 32 . However, any Wld protein in the axon below the detection level of immunostaining could still have a direct protective role.
Nmnat is a nuclear protein and the only known mammalian enzyme catalyzing the reaction NMN + ATP → NAD + + PPi (ref. 20) , a reaction generally assumed not to be at equilibrium because of the constitutive action of pyrophosphatases. Thus, the increase in Nmnat activity in Wld S should increase NAD + synthesis, and the maintenance of normal steady-state levels suggests that the putative additional NAD + is metabolized. The product of a compensatory reaction could itself be involved in axon protection. For example, poly-ADP ribosylation uses NAD + , influencing protein activity and cellular NAD + and ATP content, especially in response to stress 33, 34 . Mild activation of PARP without NAD + depletion can be neuroprotective 35 . Another metabolite, NADPH, is a coenzyme for nitric oxide synthase, an enzyme linked to axon damage 36 , and synthesis of the signaling molecule cyclic ADP ribose from NAD + regulates calcium release from intracellular stores 37 , potentially influencing calcium activated proteases in Wallerian degeneration.
Both spontaneous and transgenic Wld S mice could be used to investigate the function of each parent gene. We already show that overexpression of Nmnat activity causes no overt phenotype, and report an in vivo mutation of a mammalian E4 ubiquitination factor. Despite the critical role played by the ubiquitin-proteasome pathway in neurological disease and many other processes, we know remarkably little about the function of such proteins.
Identification of the Wld gene facilitates studies to determine whether it protects axons in clinically relevant situations. The Wld S mutation is already known to protect neuronal processes in vitro from the toxic effects of vincristine 13 , indicating that traumatic and toxic axon death share a common final pathway. Current studies indicate that distal axon loss in myelin protein zero knockout mutants 38 is rescued by Wld S (M. Samsam and R. Martini, unpublished data), and that Wld S protects in a mouse model of motoneuron disease (A. Ferri and A.C. Kato, unpublished data). Studies of Wld S in diverse neurological diseases is facilitated by our identification of the Wld gene and by recent protocols for tracking the inheritance of Wld S in crosses with neurological disease mutants 39 . Models of common and complex neurological disorders such as multiple sclerosis and diabetic neuropathy can now be investigated through the development of viral vectors for Wld and generation of transgenic Wld S rats. Mutational analysis in human neurological disorders with a homologous chromosomal location, such as hereditary Parkinsonism 40 , also becomes possible. Delayed Wallerian degeneration also alters the glial response to injury, as in a mouse model of spinal cord injury, where it delays inflammatory cell and astrocytic responses 9, 41 . It may be that this information could be used to optimize tissue destruction and repair processes.
We conclude that the Wld gene is a chimera of Ube4b and Nmnat encoding a predominantly nuclear protein in neurons, and we propose that other factors may mediate the protective effect on the axon. Axon protection is strongly dose-dependent and pyridine nucleotide metabolism is altered in the Wld S mouse. These findings open the way to a molecular understanding of Wallerian degeneration and to much-needed neuroprotective strategies that target not only the cell body, but also the axons and synaptic terminals. Supplementary Fig. 3 ). Wld protein was thus expressed in neurons, where it has an intrinsic effect 2, 7, 8 , and other cell types, where Wld S mice also express it (Fig. 5) . A 6-kb fragment containing promoter, cDNA and polyadenylation signal was released using NdeI and EcoRI and gel-purified using QIAquick extraction (Qiagen, Hilden, Germany). Pronuclear injection into CBA X C57 F1 single-cell embryos (G. Kollias, Vari, Greece) resulted in nine founders from 62 pups.
Genotyping of transgenic mice. DNA was prepared from a 5-mm tail biopsy using the Nucleon HT kit (Amersham Pharmacia, Freiburg, Germany). The 1.1-kb transgene coding region was detected using alkaline Southern blotting of a BamHI/HindIII double digest on Hybond N+ (Amersham Pharmacia) and hybridization with a corresponding 32 P-labeled probe.
Sciatic nerve lesion. Six-to eleven-week-old mice were anesthetized intraperitoneally with Ketanest (100 mg/kg; Bayer, Leverkusen, Germany) and Rompun (5 mg/kg; Parke Davis/Pfizer, Karlsruhe, Germany). Right sciatic nerves (upper thigh) were transected and the wounds were closed with single sutures. Two to fourteen days later, mice were killed, the swollen first 2 mm of the distal nerve was discarded, the next 2 mm was used for light and electron microscopy, and a segment 4-10 mm distal to the lesion site was used in western blotting. Further distal nerves and muscles were used for electrophysiology.
Light and electron microscopy. Nerve segments were fixed for 1-3 days in fresh half-strength Karnovsky's fixation (4% paraformaldehyde, 2% glutaraldehyde in 0.1 M sodium cacodylate, pH 7.3; ref. 43) , extensively buffer-rinsed and osmicated for 4 h with 1% OsO 4 in 0.1 M cacodylate. Samples were taken through a graded ethanol series including a uranylic acetate en bloc staining step overnight in 70% ethanol. Before infiltration with Araldite Cy212 epoxy resin (Serva, Heidelberg, Germany), propylene oxide was used as intermedium. Tissue blocks were cured for 60 h at 60°C. Semithin (0.5 µm) and thin (60 nm) cross-sections were taken on a Reichert Ultracut UCT ultramicrotome. Semithin sections for light microscopy were stained with methylene blue and thin sections, with 1% aqueous uranylic acetate (20 min), and sections were counterstained with Reynold's lead citrate (7 min) 44 . Thin sections were mounted on 150 mesh Formvar coated copper grids and examined with a Zeiss EM 902 electron microscope at 80 kV acceleration voltage.
Neuromuscular junction electrophysiology and morphology. FDB and lumbrical muscles and contralateral controls were removed in Cologne and placed in cold physiological saline (137 mM Na + , 4 mM K + , 2 mM Ca 2+ , 1 mM Mg 2+ , 147 mM Cl -, 5 mM glucose, 5 mM HEPES, pH 7.2-7.4, equilibrated with air or 100% oxygen). Electrophysiological experiments were done later the same day in Edinburgh, following transfer to a medium containing similar concentrations of Na + , K + , Ca 2+ and Mg 2+ , plus 23 mM HCO 3 -, 2 mM H 2 PO 4 -, equilibrated with 95% O 2 /5% CO 2 . MEPPs and evoked synaptic responses to tibial nerve stimulation (EPPs) were recorded from FDB using an intracellular glass microelectrode and analyzed using WinWCP software 45 (J. Dempster, University of Strathclyde). Recycled synaptic vesicles of motor nerve terminals were stained in lumbrical muscles using FM1-43 (Molecular Probes, Leiden, Netherlands) with 20 Hz nerve stimulation or depolarizing physiological solutions, and acetylcholine receptors subsequently stained with TRITC-α-bungarotoxin (Molecular Probes) 46, 47 . Endplates and terminals were examined in a Nikon fluorescence microscope (Kingston-upon-Thames, UK) using respectively a standard rhodamine filter cube and a customized cube with a 435 nm excitation filter, 455 nm dichroic mirror and a 10 nm bandpass 515 nm emission filter 46 .
Conventional immunocytochemical and fluorescent bungarotoxin probes were used for structural analysis. Muscle preparations, fixed for 60 min in 0.1 M PBS, 4% paraformaldehyde, were incubated in TRITC-α-bungarotoxin (5 µg/ml; 30 min) followed by overnight primary antibody (1:200 monoclonal anti-165 kDa neurofilament plus anti-synaptic vesicle antigen SV2, Developmental Studies Hybridoma Bank, University of Iowa; or affinity purified rabbit polyclonal N70; see below). Secondary antibodies (1:200 dilution; 4 h) were FITC-conjugated sheep-anti-mouse IgG or anti-rabbit IgG (Diagnostics Scotland). Preparations were mounted in Vektashield (Vector Labs, Burlingame, California) and viewed in a fluorescence microscope using a Leitz 50× water immersion objective lens (NA 1.00; Wetzlar, Germany). Most images were captured with a Hamamatsu C5810 chilled color CCD camera and acquired using Openlab software (Improvision, Coventry, UK). Confocal images were obtained using a BioRad Radiance 2000 system (Hemel Hempstead, UK).
Western blotting. We analyzed Wld protein expression level in mouse brains homogenized in two volumes of 20 mM HEPES (pH 7.5), 0.2 M CaCl 2 , 0.2 M MgSO 4 , 1 ml/20 g tissue protease inhibitor cocktail (Sigma, Taufkirchen, Germany) and 1 mg/ml DNase (Sigma). Cytoskeletal protein preservation was determined in lesioned sciatic nerves homogenized in 20 volumes of this buffer. Proteins were separated using standard SDS-PAGE and semi-dry blotted onto nitrocellulose. Loading and transfer were checked using Ponceau S (Sigma) and Coomassie Blue. Primary antibodies were applied (overnight, 4°C) followed by horseradish peroxidase-coupled secondary antibody (1 h, room temperature; goat-anti-mouse 1:3,000, goat-anti-rabbit 1:5,000; Dianova, Hamburg, Germany) and detection using enhanced chemiluminescence (Amersham Pharmacia). Chimeric protein expression was quantified using affinity-purified N70 antibody (below) and β-tub 2.1 (Sigma) control and Quantity One software (BioRad). Cytoskeletal protein degradation was analyzed using phosphate-independent monoclonal N52 (1:2,000; Sigma) against heavy neurofilament protein.
Morphological quantification of axon preservation. We counted 500-1500 myelinated axons in randomly chosen fields 2-4 mm distal to a sciatic nerve lesion in transverse semithin sections on a Zeiss Axiophot microscope (Göttingen, Germany) coupled to a digital camera. Survival criteria were normal myelin sheaths, uniform axoplasm and intact mitochondria, supported by electron microscopy spotchecks. Scoring was documented with Meta Imaging software (Universal Imaging Corporation, Downingtown, Pennsylvania). Standard errors of the mean and ttests were calculated using SPSS for Windows 10.0.
Cloning and expression of recombinant proteins. Constructs were generated to express in bacteria the N-terminal 70 amino acids (N70) of the chimeric protein and full-length chimeric protein. Inserts were PCRamplified from transgene construct using Pfx polymerase (Life Technologies). Primers for N70 were5´-GACTAGCTAGCATGGAGGAGCTGA GCGCTGAC-3´ and 5´-ATCCGCTCGAGCTAGTCTGCTGCACCTATG GGGGA-3´.
For full-length chimeric cDNA, the second primer was replaced by 5´-CGCCTCGAGTCACAGAGTGGAATGGTTGTGC-3´.
Products were ligated into NheI/XhoI double-digested pET-28b (+) vector (Novagen, Schwalbach, Germany) and transformed into XL-10 Gold (Stratagene, Amsterdam, Netherlands). Plasmids isolated using the Plasmid Mini Kit (Qiagen) were retransformed into BL21 (DE3) (Novagen). Protein expression was induced with 1 mM IPTG for 3 h at OD 600 = 0.8. For analysis of Nmnat activity, cells were lysed by sonication.
Generation of polyclonal antisera. The N70 bacterial pellet was resuspended in native binding buffer (20 mM sodium phosphate, 500 mM sodium chloride pH 7.8,100 µg/ml egg white lysozyme), sonicated on ice (6 × 15 s with 15-s intervals) and centrifuged (3,000 g, 15 min). N70 was purified using a ProBond column (Invitrogen, Groningen, Netherlands) and concentrated using a YM-3 Centricon centrifugal filter (Millipore, Bedford, Massachusetts). Antisera were raised by intradermal immunization of two SPF-rabbits by Eurogentec (Seraing, Belgium) with boosts at days 14, 28 and 56, and a final bleed at 80 days.
For affinity purification 500 µg N70 protein bound to ProBond resin (2 ml wet volume) was blocked with 5% (w/v) dried skimmed milk powder plus 1% (w/v) BSA in native binding buffer. Resin was incubated with crude antiserum (2 ml in 8 ml binding buffer), and washed with 10 articles bed volumes binding buffer. Specific antibodies, binding only Wld protein and Ube4b, were eluted with 100 mM ethanolamine (pH 11.5), neutralized with 1.5 M Tris and dialyzed against PBS.
Immunocytochemistry of spinal cord, nerves and brain. Perfusionfixed tissues were fixed for a further four hours in 4% paraformaldehyde, 0.1 M PBS before embedding in paraffin. Paraffin sections on poly-L-lysine coated slides were dewaxed, washed in PBS, rinsed in citrate buffer overnight (60°C) and incubated with 0.1% Triton X-100 (Sigma). After blocking (5% BSA in PBS), the following primary antibodies were applied (overnight, 4°C): affinity purified N70 (above), plus monoclonal anti-MAP2 (Sigma), mouse polyclonal anti-GFAP (Sigma) or monoclonal anti-neurofilament (Biogenex, San Ramon, California). Secondary antibodies (1 h, room temperature) were either Cy3-labeled goat-anti-rabbit (Dako, Hamburg, Germany) or Texas Red-labeled goat-anti-rabbit (Molecular Probes) together with Cy2-labeled goat-anti-mouse (both Dako), diluted according to the manufacturers' instructions.
Determination of NMNAT activity. Mice were killed, and whole brains were immediately removed and cut into two equal hemispheres for NMNAT assay and NAD + determination, respectively. Tissue was suspended in 3 volumes of 100 mM Tris-HCl, pH 7.4, 0.5 mM EDTA, 1 mM MgCl 2 , 1 mM DTT, 1 mM PMSF and homogenized on ice (3 × 3 s with 10-s intervals) using an Ultra-Turrax homogenizer at medium speed. NMNAT activity was determined using a reaction mixture of 40 mM Tris-HCl pH 7.5, 5 mM nicotinamide mononucleotide (NMN), 3.4 mM ATP, 18 mM MgCl 2 , 10 mM NaF, and brain homogenate (final volume of 0.5 ml). The reaction was started by the addition of NMN at 37°C and stopped after 10-40 min by adding 100 µl of assay mixture to 50 µl of ice-cold 1.2 M HClO 4 . After 10 min, at 0°C the mixture was centrifuged and 130 µl of supernatant was neutralized by addition of 35 µl 0.8-M K 2 CO 3 . NMNAT activity was calculated after HPLC identification and quantification of NAD + produced 48 . One unit of enzyme activity catalyses the synthesis of 1 µmol of NAD + per minute at 37°C.
Determination of NAD + content. A brain hemisphere in 2 volumes 7.5% ice-cold HClO 4 was homogenized using an Ultra-Turrax (4 × 4 s, with 20 s intervals). After 15 min at 0°C, the suspension was centrifuged at 16,000 g for 1 min. The pH was adjusted to 6.0 using 0.8 M K 2 CO 3 . After centrifugation, the extract was analyzed by HPLC 48 .
Animal experimentation was approved by Stadt Köln Veterinäramt, licence K13,11//00.
GenBank accession numbers. The GenBank accession number for
NMNAT is AF312734; for Wld, AF260924.
